Prostate Cancer

Alicia Morgans, MD, MPH, discusses the ARANOTE trial.

An expert discusses how radiopharmaceuticals such as radium-223 offer a valuable different mechanism of action in treating advanced prostate cancer, requiring careful patient selection, safety monitoring including complete blood count (CBC) tracking, and practical management of adverse effects such as fatigue and nausea while following radiation safety protocols.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

Enzalutamide and leuprolide significantly enhance survival in high-risk nonmetastatic prostate cancer, offering new hope for early intervention.

An expert discusses how the PEACE III combination of radium-223 and enzalutamide represents an effective treatment option for the limited population of patients who reach first-line metastatic castration-resistant prostate cancer (mCRPC) without prior androgen receptor pathway inhibitor exposure, while other combinations such as radium-223 plus olaparib showed mixed results with concerning toxicity profiles.

Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response rates in intermediate-to-high-risk prostate cancer.

The ongoing ARASTEP trial evaluates darolutamide plus ADT vs placebo for high-risk prostate cancer biochemical recurrence with PSMA PET-CT-positive lesions, aiming to improve rPFS.

Olaparib and radium-223 bested radium-223 alone in radiographic progression-free survival in men with castration-resistant prostate cancer.

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic castration-sensitive prostate cancer.

Darolutamide significantly delayed pain progression and improved overall well-being in patients with metastatic hormone-sensitive prostate cancer.

Niraparib with AAP cut the risk of progression or death by 37% in HRR-altered mCSPC, according to data from the AMPLITUDE trial.

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall survival.

The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer.

PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of phase 2 meeting.

Talazoparib plus enzalutamide significantly delayed the deterioration of global health status and quality of life in patients with mCRPC in the TALAPRO-2 study.

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, which focused on Black patients with metastatic hormone-sensitive prostate cancer.

An ARANOTE substudy showed darolutamide plus ADT significantly improved outcomes (rPFS HR 0.51) and PSA suppression in Black men with mHSPC, with similar safety to overall trial.

A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.

Prostatectomy for grade group 1 prostate cancer significantly decreased from 2010 to 2024 in SEER and MUSIC data. Remaining cases show more high-risk features.

Frailty assessments, particularly the G8 tool, BMI, and albumin, may identify mHSPC patients at higher risk for severe adverse events with upfront docetaxel, a study suggests.

The EMBARK analysis showed most men regained testosterone after stopping enzalutamide/leuprolide or placebo/leuprolide for prostate cancer with good PSA response, and recovery was common across age groups.

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, focusing on Black patients with metastatic hormone-sensitive prostate cancer.

Sophia Kamran, MD, discusses how salvage therapy after biochemical recurrence may improve outcomes for patients with prostate cancer.

Levee Medical has begun its pivotal ARID II trial, studying the Voro Scaffold for improved continence after prostatectomy.